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ABSTRACT
The aim of this study was to describe the results of a Brazilian Consensus on Small Fiber Neuropathy (SFN). Fifteen neurologists (members of 
the Brazilian Academy of Neurology) reviewed a preliminary draft. Eleven panelists got together in the city of Fortaleza to discuss and finish the 
text for the manuscript submission. Small fiber neuropathy can be defined as a subtype of neuropathy characterized by selective involvement 
of unmyelinated or thinly myelinated sensory fibers. Its clinical picture includes both negative and positive manifestations: sensory (pain/
dysesthesias/pruritus) or combined sensory and autonomic complaints, associated with an almost entirely normal neurological examination. 
Standard electromyography is normal. A growing list of medical conditions is associated with SFN. The classification of SFN may also serve 
as a useful terminology to uncover minor discrepancies in the normal values from different neurophysiology laboratories. Several techniques 
may disclose sensory and/or autonomic impairment. Further studies are necessary to refine these techniques and develop specific therapies.
Keywords: small fiber neuropathy; unmyelinated nerve fibers.
RESUMO
O objetivo deste estudo é descrever os resultados de um Consenso Brasileiro sobre Neuropatia de Fibras Finas (NFF). Quinze neurologistas 
(membros da Academia Brasileira de Neurologia) revisaram uma versão preliminar do artigo. Onze panelistas se reuniram na cidade de Fortaleza 
para discutir e terminar o texto para a submissão do manuscrito. NFF pode ser definida como um subtipo de neuropatia caracterizada pelo 
envolvimento seletivo de fibras sensitivas amielínicas ou pouco mielinizadas. Seu quadro clínico inclui manifestações negativas e positivas: 
sensitivas (dor/disestesias/prurido) ou queixas sensitivas e autonômicas combinadas, associadas a exame neurológico quase totalmente normal. A 
eletromiografia convencional é normal. Uma lista crescente de condições médicas causa NFF. NFF também pode servir como uma terminologia útil 
para referenciar pequenas discrepâncias nos valores normais de diferentes laboratórios de neurofisiologia. Diferentes técnicas podem evidenciar 
anormalidades sensitivas e/ou autonômicas. São necessários mais estudos para refiná-las e para o desenvolvimento de terapias específicas.
Palavras-chave: neuropatia de pequenas fibras; fibras nervosas amielínicas.
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Neuropathy is a common product of several medical 
conditions. Peripheral nerves may be damaged by a wide 
range of mechanisms, including metabolic, infectious, nutri-
tional, vascular, genetic and auto-immune disorders. Single 
nerve damage is called mononeuropathy, while patchy, com-
bined but noncontiguous (non-length dependent) nerve 
involvement is called mononeuropathy multiplex. When 
peripheral nerves are affected symmetrically (usually in a 
length-dependent fashion), the disease process is called poly-
neuropathy. In addition to the topographical distribution, 
neuropathies may be classified according to several charac-
teristics, among them the subset of nerve fibers involved. 
A very particular group of peripheral neuropathies is the 
one due to selective involvement of small fibers, the so-called 
“small fiber neuropathies” (SFN). Despite a major recent 
interest in SFN, several aspects related to these conditions 
are still controversial. This assertion can be illustrated by the 
lack of specific chapters devoted to the discussion of SFN in 
classic peripheral neuropathy textbooks.
In most instances, unmyelinated or thinly myelinated 
sensory fibers are affected, but autonomic fibers may be 
also affected; in this case accompanied by autonomic man-
ifestations. Rarely, neuropathies may involve only fibers 
devoted to autonomic functions (autonomic neuropathies). 
Those conditions are usually considered as a particular 
group and will not be included in this consensus. The aim 
of this study was to summarize the results of a Consensus 
from the Scientific Department of Peripheral Neuropathies 
of the Brazilian Academy of Neurology, which was designed 
to define and diagnose SFN. Part of it has been reported in 
abstract form elsewhere1.
METHODS
After identifying the need to generate a text to discuss the 
definition and methodology for the diagnosis of SFN, a group 
of 15 Brazilian neurologists, members of the Peripheral 
Neuropathy Scientific Department of the Brazilian Academy 
of Neurology and considered to be representative experts on 
the subject, was formed. 
The first author produced a draft summarizing the main 
views on the subject and emailed the text to 12 other spe-
cialists. This number was subsequently increased to 15, 
since two participants informed that they were not going to 
attend the face-to-face meeting. Each participant reviewed 
the whole text, and was also responsible for focusing his/
her review on a specific topic. A preliminary review was 
emailed by each participant to the coordinator and a sec-
ond text was emailed to the panelists. After four months, 
11 panelists got together in the city of Fortaleza to discuss 
the controversial points and vote for the final text of the 
recommendations. Four original panelists could not attend 
the face-to-face meeting, but since they had collaborated by 
email and Internet discussion, and agreed with the final text, 
the total number of participants remained at 15. In addition 
to the main text, each participant received (by email) a list of 
papers generated by a PubMed search using the key words 
“small fiber/fibre neuropathy”, comprising a total of 1,235 
papers (search conducted on 2/3/2017).
RESULTS
Anatomical considerations
Peripheral nerves are formed by parallel bundles ( fasci-
cles) embedded in a collagenous matrix (epineurium). Each 
fascicle is separated by a perineural sheath formed by flat-
tened squamous cells connected by tight junctions (perineu-
rium). The individual motor, sensory and autonomic nerve 
fiber (axon and its associated Schwann cells) is enveloped 
by connective tissue (endoneurium), although some authors 
include the Schwann cells and axons as part of the endoneu-
rium2. In addition to different functional subtypes (motor, 
sensory and autonomic), axons can also be distinguished by 
different degrees of myelination, being highly, moderately, or 
thinly myelinated (Aδ fibers), or completely lacking a myelin 
envelope, the so-called unmyelinated fibers. 
Unmyelinated fibers (type C) can be autonomic or sen-
sory. They are surrounded by Schwann cells in a different 
way, forming the so-called Remak fibers. In 1838, Remak 
teased autonomic nerve fibers in water and differentiated 
myelinated (tubuli primitivi) from unmyelinated fibers – 
fibrae organicae3. In 1868, Langerhans described the intra-
epidermal nerve fiber endings4. Sixty years later, Remak and 
Tuckett identified both Schwann cells and axons3. Joseph 
Erlanger and Herbert Spencer Gasser won the Nobel Prize 
in 1944 for their studies on the differential functions of sin-
gle nerve fibers. Unmyelinated axons range in diameter from 
0.2 μm to 3 μm and in men there are 1–4 axons per Schwann 
cell unit3. The proportion of myelinated to unmyelinated 
fibers in the sural nerve is 1:45. The presence of myelin in very 
thin fibers does not increase the conduction speed and its 
absence makes unmyelinated fibers more resistant to meta-
bolic insults3. On the other hand, since unmyelinated fibers 
are not insulated from each other, impulses conducting in 
one axon may spread to neighboring axons3.
New histological evidence from skin biopsies completely 
changed the concept of SFN, as it revealed that axons lose 
the Schwann cell ensheathment as they cross the dermal-
epidermal junction6. However, since the loss of distal nerve 
endings may indicate the loss of distal fibers from more 
prominently myelinated sensory fibers, distal nerve fiber 
loss may be due to a less specific sensory involvement, 
which could include myelinated sensory fibers (e.g. mediat-
ing vibration and proprioception) amenable to assessment 
by electromyography. This controversial aspect will be dis-
cussed further in the next sections.
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Definition and clinical subtypes of small 
fiber neuropathy
The term “small fiber neuropathy” was first employed by 
Stewart et al.7 From the clinical point of view, SFN is defined 
as a syndrome characterized by sensory or combined sen-
sory and autonomic manifestations, associated with an 
almost entirely normal neurological examination (except for 
possible distal pinprick and thermal loss) or at least abnor-
malities solely associated with small fiber involvement (e.g. 
orthostatic hypotension).
Small fiber neuropathy may present as negative and posi-
tive manifestations. For the sensory subtype of SFN, positive 
manifestations usually dominate the clinical picture. Patients 
may complain of dysesthesias, burning, stinging, tingling sen-
sations and neuropathic pain (length-dependent), usually 
more severe in the evening. Additional complaints include 
formication-like phenomena and chronic pruritus8. Patchy or 
non-length dependent symptoms have also been described.
The exclusive autonomic subtype has a broader range 
of manifestations, that can be easily mimicked by several 
other medical conditions, such as dizziness (due to ortho-
static intolerance or orthostatic hypotension), syncopal 
spells, anhidrosis or hyperhidrosis, decreased lacrima-
tion, decreased salivation, important trophic skin changes, 
changes in bowel habits (constipation or diarrhea) or urinary 
complaints (polyuria, urinary retention or incontinence), 
among others ( for a more extensive review of autonomic 
manifestations, the reader is referred to authoritative texts 
on autonomic diseases). Although they technically belong 
to the same group of SFN, autonomic neuropathies are usu-
ally studied separately from sensory SFN. Therefore, the term 
SFN is usually employed to discuss variants that course with 
sensory changes (pure or associated with autonomic find-
ings) and herein we follow this same clinical tradition.
A non-length dependent variant of SFN has recently 
been reported and will not be discussed in detail in this 
review, but the reader is referred to: Brannagan et al.9; and 
Khoshnoodi et al.10. Conditions, like diabetes mellitus, may 
be associated with forms of SFN associated with combined 
sensory and autonomic involvement that seems to be the 
most prevalent subtype11. It is important to highlight, that in 
addition to unusual clinical symptoms such as formication-
like phenomena and chronic pruritus8, SFN may be associ-
ated with acute neuropathy symptoms (Guillain-Barré-like 
syndrome), minimal clinical symptoms (subclinical neuropa-
thy) or other controversial clinical entities, such as restless 
leg syndrome4,11.
Neurological examination in patients with small 
fiber neuropathy
Neurological examination may be normal, usually at the 
very early onset of the disease, but eventually pain and ther-
mal sensations will decrease in a length-dependent fashion in 
polyneuropathies, following the nerve territories in multiple 
mononeuropathies, and in a patchy temperature-dependent 
fashion in leprosy. A mental status examination is usually 
normal, cranial nerve involvement (usually mild and late, 
except for some specific variants) may be present for both 
sensory (involvement of trigeminal sensory modalities) and 
autonomic subtypes (pupillary, salivation involvement of IX 
and X nerves). Motor examination is entirely normal (includ-
ing reflexes), although hyporeflexia also does not invalidate 
the diagnosis. Sensory examination can, and frequently does, 
reveal decreased distal pinprick and temperature sensa-
tion (length-dependent fashion). There is no agreement on 
whether minor distal vibratory involvement is acceptable 
or not. Autonomic abnormalities may be seen on examina-
tion, including changes in skin temperature and color as well 
as in sweating pattern. Other changes on physical examina-
tion may be particular to different subtypes of SFN, such as 
genetic forms, leprosy, SFN associated with systemic diseases 
and especially with the range of different autonomic disor-
ders (such as orthostatic hypotension, orthostatic tachycar-
dia). These changes will not be the subject of this consensus.
Epidemiology of small fiber neuropathy
In the normal population, there is only one study from the 
Netherlands that reported an incidence of SFN of 11.7 cases 
per 100,000 population per year, and higher rates in individu-
als older than 65 years12. The overall prevalence of neuropa-
thy is 2.4% (in those older than 65 years, it may reach 8%) 
and estimates of hereditary neuropathy are as high as 1 in 
1,214 persons6. In patients with certain types of systemic con-
ditions, SFN can be highly prevalent, e.g. celiac and inflam-
matory bowel diseases13,14,15. Small fiber neuropathy is a com-
mon presentation of axonal idiopathic polyneuropathy or 
cryptogenic sensory polyneuropathy. In a cooperative study 
involving two North American sites and one South American 
(Federal Fluminense University in Brazil), cryptogenic sen-
sory polyneuropathy made up 25% of neuropathy cases16.
Electromyography testing
Nerve conduction parameters can be significantly 
affected by several physiological factors, such as body tem-
perature, height, age, anatomical variations and anatomical 
differences. Normal values for the different neurophysiolog-
ical parameters are not universally accepted. Each neuro-
physiology laboratory is responsible for setting up the nor-
mal values and usually employs a slightly different profile of 
common neurophysiological techniques. In addition, most 
neurophysiology laboratories do not have adequate normal 
values for different age groups. Since most patients undergo-
ing evaluation for peripheral neuropathy have not had prior 
electrodiagnostic testing, it is also theoretically possible 
that a given neurophysiological parameter, such as sensory 
or motor amplitude, may be within the normal range for a 
certain neurophysiology laboratory but still reflect an unex-
plained decrease for a given time interval. Therefore, a normal 
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nerve conduction study cannot exclude minor large-fiber 
axonal decrements. This may explain why a patient labeled 
with SFN may indeed have a minor decrement of distal vibra-
tion. In this regard, although not necessarily entirely true for 
all cases, the current terminology and concept of SFN may 
serve as an important concept for the diagnosis of peripheral 
neuropathy itself and avoid confusion (labeling a patient with 
symptomatic neuropathy as normal because of normal EMG 
results) generated by diverse neurophysiological sets of nor-
mal values within the laboratory tests.
Mechanisms of selective small fiber involvement
Although, most commonly, all types of peripheral axons 
(motor, sensory and autonomic) are affected by a specific 
pathogenic mechanism, different disease processes can lead to 
more selective involvement of a particular axon subtype, due to 
variable reasons. Diffuse unmyelinated and thinly myelinated 
fibers can be affected separately in SFN. The most common 
site of small fiber involvement is at the distal nerve branches 
at the skin, although non-length-dependent involvement has 
been described. Here, we provide a growing list of conditions 
that can lead to selective small fiber involvement in humans, 
at least during part of the natural course of the condition 
(Table)11,13,14,15,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,333,34,35,36,37,38,39,40,41,42,43,44.
As we discuss in the next sections, pure (isolated) involve-
ment of small nerve fibers may be difficult to pinpoint. Most 
commonly, at least a milder degree of combined large-fiber 
involvement is observed, leading us to conclude that, “pure” 
small fiber involvement is, in several instances, a fallacy. 
Selective small fiber involvement can only be explained by 
specific genetic conditions and a few auto-immune disor-
ders, as we will subsequently point out.
Tests to confirm the clinical diagnosis of 
small fiber neuropathies
By definition, as large fibers are spared in small fiber neu-
ropathies, the most classic ways to document peripheral 
nerve involvement yield a totally normal test, i.e. nerve con-
duction studies and electromyography are entirely normal in 
patients with SFN.
Therefore, specialized testing has been developed to eval-
uate the function of autonomic and unmyelinated sensory 
fibers. Although most institutions have developed different 
protocols for testing of small fibers, SFN confirmatory tests 
can grossly be divided into two subtypes: (A) tests to evaluate 
somatic (sensory) small fibers; and (B) tests to evaluate the 
function of autonomic fibers.
A - Tests for selective evaluation of 
somatic small fibers
Thermoregulatory sweat test 
The thermoregulatory sweat test consists of dust-
ing the body surface with an indicator powder (alizarin 
red or starch powder over the body surface with an aque-
ous iodine solution – Minor’s test). The powder turns from 
orange to purple or dark purple, to almost black when wet. 
The patient is kept in an enclosed cabinet with a moder-
ately hot and humid environment (45o–50oC air tempera-
ture with 35–40% relative humidity). The mean skin tem-
perature is monitored and kept between 38.5o and 39.5oC 
(overhead infrared heaters). The oral temperature must rise 
at least 1oC or to 38oC (whichever is higher). Maximal sweat-
ing is achieved in 30–65 minutes. Digital photographs of the 
sweating and non-sweating areas are taken, and a comput-
erized body image is generated. A software compares the 
sweat patterns with laboratory controls. In addition to eval-
uating peripheral small fibers, the test also evaluates pre-
ganglionic sympathetic fibers and central nervous system 
autonomic pathways45. This test is currently available in a 
few academic institutions in Brazil.
Table. Causes of small fiber neuropathy.
Metabolic and/or nutritional
Diabetes mellitus, metabolic syndrome/glucose intolerance, 
insulin neuritis11, 17
Chronic renal insufficiency18
Thiamine or B12 deficiency (myeloneuropathy spectrum)11,19
Hyper- or hypothyroidism11,20
Hyperlipidemia21
Infectious
Leprosy22
HIV23, HTLV24
Hepatitis C25
Chagas disease26
Amyloidosis
Systemic27
Familial (familial amyloid polyneuropathy)28
Autoimmune
Celiac disease15
Sjögren’s disease29
Inflammatory bowel disease13,14
Systemic lupus erythematosus30
Rheumatoid arthritis31
Sarcoidosis32
Guillain-Barré syndrome variants33
Drugs
Extensive list, chronic metronidazole, statins, anti-TNF 
inhibitor, bortezomib11,34
Toxins
Thallium, arsenic, alcohol35,36
Vaccinations37
Hereditary forms
Hereditary sensory and autonomic neuropathy, Fabry disease, 
sodium channelopathies, Wilson’s disease, Pompe disease, Fragile 
X-associated tremor/ataxia syndrome, Ehlers-Danlos syndrome
Neurodegenerative
Parkinson’s disease, Amyotrophic lateral sclerosis 42,43
Cryptogenic
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Quantitative sensory testing
Quantitative sensory tests are psychophysiological tests 
(dependent on the patient’s self-assessment and report) 
designed to evaluate the thresholds for detection of vibration, 
temperature (most commonly cold, but also warm) sensations 
and pain. Although they have been employed in several clinical 
trials (usually for both small- and large-fiber involvement), they 
have significant limitations: central loss cannot be differentiated 
from peripheral loss and feigned sensory loss cannot easily be 
differentiated46. Newer algorithms decrease the risk of feigned 
deficits and heat and heat-pain thresholds are better suited for 
small fiber assessment. This test is currently available in a few 
academic institutions in Brazil. A Brazilian version of a quantita-
tive sensory testing device has also been validated47.
Contact heat evoked potentials
Contact heat evoked potentials are potentials that are gen-
erated by a device that provides rapid cycles of heat. Their ampli-
tudes correlate with cutaneous nociceptive nerve fiber density48. 
A recent study in patients with Parkinson’s disease revealed that 
contact heat evoked potential amplitudes could be modulated 
by dopamine levels (ON and OFF stages), suggesting that evalu-
ation of small fibers may be affected by central factors when one 
uses this technique49 in contrast with a laser evoked potential 
study50. Another study concluded that small fibers are affected 
in patients with meralgia paresthetica and neuropathic pain51. 
There is a strong correlation of contact heat evoked potential 
findings with the intra-epidermal nerve fiber density observed in 
skin biopsy. A recent study reported normative data for contact 
heat evoked potentials52. This study involved several different 
international peripheral nerve centers including one in Brazil 
(Federal Fluminense University, Rio de Janeiro). This method has 
the advantage of being noninvasive and does not induce burn-
ing lesions in the area where heat stimuli are applied, contrast-
ing with the laser evoked potentials test. This test is currently 
available in very few institutions in Brazil.
B - Tests for selective evaluation of autonomic 
small fibers
Quantitative sudomotor axonal reflex testing
Quantitative sudomotor axon reflex testing evaluates post-
ganglionic sudomotor function through iontophoresis induced 
with acetylcholine applied to the skin. Several complex devices 
have been developed to accomplish this task, including a recently-
designed commercially-available machine, called QSweat53. In 
general, four sites are mapped, two distal and two proximal in 
the upper and lower extremities, allowing the evaluation of a dis-
tal-to-proximal neuropathy gradient involvement. Some authors 
have observed moderate test-retest reliability (at least for older 
versions of the quantitative sudomotor axon reflex test), suggest-
ing limitations for longitudinal assessment of sudomotor func-
tion with quantitative sudomotor axon reflex testing54. This test 
is currently available in very few academic institutions in Brazil.
Skin wrinkling test
Skin wrinkling is mediated by sympathetic activity. The 
observation that amputated fingers maintain the ability to 
vasodilate while not wrinkling supports this premise. Recent 
studies have validated osmotic and EMLA-induced skin wrin-
kling55,56. They revealed that an index of skin wrinkling from 
four fingers (all but the thumb) correlated with the fiber den-
sity in skin biopsies57. The great advantage is the low cost but 
the evaluation of skin wrinkling may be limited in hands with 
calluses or other labor-related issues. Although not very popu-
lar worldwide (despite the low cost), this test has been used in 
at least one institution (only for research purposes) in Brazil.
Sympathetic skin responses
Sympathetic skin responses are electrical potentials obtained 
in the skin by electrodes that are positioned on the palms and 
soles of the feet. Potentials are dependent on the changes in 
sudomotor activity, providing a measurement of sympathetic 
cholinergic activity58. Different stereotyped stimuli have been 
used to elicit sympathetic skin responses, such as inspiratory 
gasp, auditory stimuli (clapping of the hands) or electrical stim-
uli. The sympathetic skin response is mediated through long spi-
nal cord descending pathways and is not affected by pure auto-
nomic failure restricted to sympathetic adrenergic pathways. It 
can be absent in normal old individuals and, therefore, usually 
is not considered a very reliable test. However, since it can read-
ily be performed with most electromyography equipment, it has 
been used as a screening tool for autonomic involvement in sev-
eral centers. This test is probably the most-employed screening 
tool for autonomic involvement in Brazil.
Heart rate response to deep breathing and Valsalva 
test (cardiovagal function tests)
Due to their availability in several electromyography pack-
ages worldwide, the heart rate response to deep breathing and 
Valsalva ratio tests have frequently been used in several neuro-
physiology laboratories. The heart rate response to deep breath-
ing is affected by several factors (hypocapnia, sympathetic activ-
ity, position of the individual, medication, obesity and depth of 
breathing) but age and rate of breathing are the two most impor-
tant modulating factors. The R-R variation is maximal at rates of 
five to six breaths per minute, so the patient is instructed to estab-
lish smooth breathing at this rate (usually following an oscillating 
bar) in 10-second intervals. Eight cycles are recorded, followed 
by a five-minute rest and repeated testing. The five largest con-
secutive responses are read, averaged and the heart rate range 
derived59. The Valsalva ratio is established by asking the patient to 
maintain a column of mercury at 40 mmHg for 15 seconds via a 
bugle with an air leak, to keep an open glottis. The Valsalva ratio is 
derived from the maximum heart rate generated by the Valsalva 
maneuver divided by the lowest heart rate within the 30-second 
period of peak heart rate60. In addition to diagnostic purposes, at 
least for diabetic neuropathies, these tests can have a prognostic 
value57. Although very popular worldwide (due to the low cost), 
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these tests are only used for research purposes in Brazil (they 
were not approved for standard routine medical testing).
C - Tests for evaluation of somatic and/or 
autonomic small fibers
Skin biopsy
Skin biopsies are increasingly being employed to evaluate 
small fiber function and this is the most important diagnostic 
test to evaluate small fibers in the USA and Europe (it is starting 
to become available in Brazil but with level A recommendation 
on European guidelines). Standard 3-mm dermatologic punch 
biopsies can be taken from any part of the body, but have been 
standardized for the distal lateral leg and thigh, to demonstrate 
a length-dependent pattern58. The morphometric evaluation 
of linear density of intra-epidermal nerve fibers should include 
normative values for different genders and ages, and this has 
been considered a very safe procedure with no serious side 
effects in 35,000 biopsies over 10 years61. New technical vari-
ants have evolved to evaluate autonomic function (sweat gland 
innervation) as well as PMP22 expression and alpha-synuclein 
deposits62,63. Evaluation of older patients is less reliable due 
to higher dispersion/non-Gaussian distribution. Neuropathy 
could also be feigned by prior administration of agents that 
lead to denervation, such as capsaicin. Another drawback is 
that decreased intra-epidermal fiber density could be second-
ary to involvement of the distal portions of large sensory fibers, 
and not necessarily selective involvement of unmyelinated and 
thinly myelinated fibers, making the interpretation of the results 
of the skin biopsies more complicated. Although skin biopsy is 
considered a gold-standard test for the diagnosis of small fiber 
neuropathies in several recommendations from different soci-
eties (e.g. Lauria et al. 201061), an unequivocal clinical-histolog-
ical correlation is still under discussion. It is currently available 
at very few academic institutions in Brazil and has been used to 
evaluate HIV-related neuropathy in a Brazilian study64.
In vivo confocal microscopy
The use of confocal microscopy has recently gained attention 
in the medical literature to evaluate small fiber function. The cor-
nea is densely innervated by sensory and autonomic trigeminal 
fibers (C and Aδ fibers) and corneal confocal microscopy has also 
emerged as a new diagnostic tool to evaluate small fiber neuropa-
thy in several medical conditions. In patients with diabetes melli-
tus, several parameters of corneal confocal microscopy correlate 
with intra-epidermal nerve fiber density65. Very recently, norma-
tive data for corneal confocal microscopy from Brazil (Federal 
Fluminense University, Rio de Janeiro) have been reported66.
Grading scale of certainty for the diagnosis of small 
fiber neuropathies
There have been several attempts to develop scales for the 
diagnosis of SFN. A recent tool was designed that proposed to 
grade SFN according to clinical symptoms, signs and findings 
from validated examinations67,68. A diagnosis of ‘possible’ SFN is 
present for length-dependent symptoms and/or clinical signs 
of small-fiber damage. A diagnosis of ‘probable’ SFN is made by 
length-dependent symptoms, clinical signs of small-fiber dam-
age, and normal sural nerve conduction studies. Finally, a diagno-
sis of ‘definite’ SFN is made by length-dependent symptoms, clin-
ical signs of small-fiber damage, normal sural nerve conduction 
studies, altered intra-epidermal nerve fiber density at the ankle 
and/or abnormal quantitative sensory testing thermal thresh-
olds at the foot. These criteria have been proposed for diabetic 
SFN, but can be applied to all patients with suspected SFN, irre-
spective of the associated disease or condition. Figure 1 details 
a flowchart that we have designed for the evaluation of patients 
with suspected SFN.
QST: quantitative sensory testing; CHEPS: contact heat evoke potentials; TST: 
thermoregulatory sweat test; Q-SART: quantitative sudomotor axonal reflex test.
Figure. Schematic view of the evaluation of the patient with small 
fiber neuropathy (SFN) leading to disease classification as possible, 
probable and defined according to different test results. The lower 
part of the diagram depicts the most common forms of SFN.
SFN POSSIBLE
SFN PROBABLE
SFN DEFINED
NORMAL EMG
ABNORMAL EMG
Presence of symptoms
(pain, formication, burning,
dysesthesia) with nerve pattern
and length-dependent distribution
MINIMAL ABNORMALITIES
ON NEUROLOGIAL EXAM
except for new changes in the thermal
and pain sensitivity
SPECIFIC TESTS FOR EVALUATION
OF SMALL FIBER NEUROPATHY
QST, SKIN biopsy - intraepidermal
fiber density - or corneal confocal
microscopy
NOT SFN
Axonal or Demyelinating
neuropathy
Tests that could aid the
diagnosis of small-fiber
neuropathy: QST, TST, CHEPS,
Q-SART, in vivo confocal
corneal microscopy,
intraedpidermal fiber density,
Skin wrinkling test.
IDIOPATHIC AND ACQUIRED:
Metabolic: DM, glucose intolerance,
insulin neuritis, vitamin deficiency;
renal insufficiency; thyroid
dysfunction, hyperlipidemia;
Connective tissue and
immune-mediated disorders:
rheumatoid arthritis, Lupus,
Fibromyalgia; Sjogren,
GBS Sensitive Variant
Others: infections, drug related
(alcohol, metronidazole, statins),
celiac and inflammatory bowel
disease, sarcoidosis.
Full list - TABLE 1HEREDITARY:Sodium channel
mutations (Nav1.7,
Nav 1.8), COL6A5,
PAF, Fabry disease,
HSAN types II, III
and IV.
SFN 82%18%
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high prevalence of leprosy in several regions, leprosy screen-
ing (or at least clinical consideration) in patients with SFN 
is mandatory. Also, it is important to consider the diagno-
sis of familial amyloid neuropathy, a condition that has been 
detected in some areas in Brazil.
CONCLUSIONS
SFN represents a controversial and heterogeneous group 
of disorders. The main characteristic is a disproportional rep-
ertoire of sensory neuropathic complaints in a patient with 
an almost entirely normal neurological examination and 
conventional electromyography testing. Although not neces-
sarily entirely true for all cases, the current label of SFN may 
serve as an important aid for the diagnosis of peripheral neu-
ropathy and avoid confusion (naming a patient with neurop-
athy and normal electrodiagnostic testing as “normal”) gen-
erated by diverse neurophysiological sets of normal values 
within different laboratory tests.
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